摘要
目的:探讨倍他乐克联合胺碘酮治疗冠心病伴快速性心律失常的临床疗效。方法:回顾性分析2018年9月—2020年11月我院收治的CHDwT患者64例为此次研究对象。根据治疗方法不同分为对照组(n=32)和观察组(n=32)。对照组给予倍他乐克,观察组在对照组基础上联合给予胺碘酮,比较两组临床疗效、心电图指标、心率及心绞痛发作情况。结果:观察组治疗总有效率为96.87%,高于对照组的78.12%(P<0.05);观察组最大QT间期、最小QT间期高于对照组(P<0.05);观察组心率波动小于对照组(P<0.05);随访12个月,观察组心绞痛发生风险低于对照组(HR=0.41,95%CI:0.18~0.89,P<0.05)。结论:倍他乐克联合胺碘酮治疗冠心病伴快速性心律失常的疗效确切,可降低患者心率和心绞痛发作风险。
Objective:To explore the clinical efficacy of betaloc combined with amiodarone in the treatment of coronary heart disease with tachyarrhythmia.Methods:A total of 64 patients with CHDwT admitted to our hospital from September 2018 to November 2020 were analyzed retrospectively.They were divided into control group(n=32) and observation group(n=32) according to different treatment methods.The control group was given betaloc,and the observation group was given amiodarone on the basis of the control group.The clinical efficacy,ECG indicators,heart rate and angina attack of the two groups were compared.Results:The total effective rate of treatment in the observation group was 96.87%,which was higher than 78.12% in the control group(P<0.05).The maximum and minimum QT intervals in the observation group were higher than those in the control group(P<0.05).The heart rate fluctuation in the observation group was smaller than that in the control group(P<0.05).Following up for 12 months,the risk of angina pectoris in the observation group was lower than that in the control group(HR=0.41,95%CI:0.18-0.89,P<0.05).Conclusion:Betaloc combined with amiodarone is effective in the treatment of coronary heart disease with tachyarrhythmia,which can reduce the heart rate and the risk of angina pectoris.
作者
刘锐领
于文华
LIU Ruiling;YU Wenhua(Department of Cardiology,Tianjin Jinghai District Hospital,Tianjin 301600,China)
出处
《中国药物滥用防治杂志》
CAS
2023年第4期644-646,657,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
